Novel regenerative-cell commercialization examines industry implications and clinician perspectives. It offers practical context on access, ethics, and translation.
Key Takeaways
- Newly validated pluripotent-like platform enters the US market
- By establishing a footprint across an initial network of authorized providers in Florida
- Unselected mesenchymal cultures and the oncogenic anxieties surrounding induced pluripotent platforms